sofosbuvir has been researched along with telaprevir in 30 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 28 (93.33) | 24.3611 |
2020's | 2 (6.67) | 2.80 |
Authors | Studies |
---|---|
Chen, JH; Huang, MH; Ji, XY; Jiang, JD; Jin, J; Li, ZR; Peng, ZG; Yi, H; Zhang, L; Zheng, GH | 1 |
Cen, S; Chen, J; Jiang, X; Jiang, Z; Jin, J; Li, J; Li, Y; Li, Z; Peng, Z; Quan, Y; Tan, J; Wang, Y | 1 |
Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
Mangia, A; Mottola, L | 1 |
Chen, WC; Lee, JC; Lin, CK; Sun, HY; Tseng, CK; Wang, SW; Wu, YH; Young, KC | 1 |
Boccaccio, V; Bruno, S | 1 |
Dieterich, DT; Martel-Laferrière, V | 1 |
Chung, RT; deLemos, AS | 1 |
Andronescu, CI; Andronescu, D; Diaconu, S; Purcarea, RM; Tiuca, N | 1 |
Bruno, R; Cabibbo, G; Cammà, C; Craxì, A; Enea, M; Gasbarrini, A; Macaluso, FS; Petta, S; Plaia, A | 1 |
Arends, JE; Burger, DM; de Kanter, CT; de Knegt, RJ; Drenth, JP; Reesink, HW; van der Valk, M | 1 |
Ahmed, A; Gordon, SC; Park, H; Saab, S; Sulkowski, M; Younossi, Z | 1 |
Firpi, RJ; Hilgenfeldt, E | 1 |
Brochot, E; Capron, D; Castelain, S; Duverlie, G; François, C; Helle, F; Nguyen-Khac, E | 1 |
Coilly, A; Duclos-Vallée, JC; Roche, B; Samuel, D | 1 |
Luo, R; Nong, J; Qing, J; Shao, Y; Sun, Y; Tang, R; Wang, Y; Wu, M; Yin, Z; Yu, X | 1 |
Domingo, E; Esteban, JI; Gallego, I; Gregori, J; Moreno, E; Perales, C; Quer, J; Rice, CM; Sheldon, J | 1 |
Brügger, U; Girardin, F; Goossens, N; Negro, F; Perrier, A; Riguzzi, M; Vernaz, N | 1 |
Ross, JS; Sangaralingham, LR; Shah, ND; Talwalkar, JA; Yao, X | 1 |
Durlik, M; Hreńczuk, M; Kosieradzki, M; Małkowski, P; Pacholczyk, M; Sowińska, R; Tronina, O | 1 |
Yu, ML | 1 |
Boucher, E; Chapman, W; Cheslock, P; Chung, RT; Curry, MP; Mantry, P; Molrine, DC; Schiano, TD; Smith, HL; Wang, Y | 1 |
Bae, YS; Bartenschlager, R; Jo, E; Kim, HY; Lee, JY; Lee, M; Shin, EC; Windisch, MP; Yang, J | 1 |
Bourlière, M; Carrat, F; Carrieri, MP; Fontaine, H; Hézode, C; Marcellin, F; Petrov-Sanchez, V; Protopopescu, C; Vilotitch, A; Younossi, Z | 1 |
Fernández-Cuenca, F; López-Hernández, I; Paniagua-García, M; Ríos-Villegas, MJ | 1 |
Al Marzooqi, SH; Cerocchi, O; Duarte-Rojo, A; Feld, JJ; Harrell, SM; Janssen, HLA; Karkada, J; Klair, JS; Kowgier, M; Maan, R; Rhodes, KD | 1 |
Alfieri, R; Andreoni, M; Angelico, M; Antonucci, FP; Babudieri, S; Bernardini, S; Biliotti, E; Bolis, M; Calvaruso, V; Casalino, P; Ceccherini-Silberstein, F; Cento, V; Cerrone, M; Craxì, A; D'Arminio Monforte, A; Danieli, E; Di Biagio, A; Di Carlo, D; Di Maio, VC; Di Paolo, D; Gianserra, L; Guedj, J; Lenci, I; Magni, CF; Melis, M; Menzaghi, B; Micheli, V; Nguyen, THT; Nicolini, LA; Parruti, G; Pasquazzi, C; Perno, CF; Polilli, E; Puoti, M; Quirino, T; Rizzardini, G; Romagnoli, D; Sarmati, L; Siciliano, M; Taliani, G; Teti, E | 1 |
Anderson, R; Avellar, AM; Castro, R; Hyde, C; Jorge, MJ; Mujica-Mota, R; Perazzo, H; Romero, C; Silva, JC; Silva, PS; Veloso, VG | 1 |
Jiang, JD; Li, YH; Lv, XQ; Mei, L; Peng, ZG; Song, DQ; Tang, S; Zhang, JP; Zhang, X | 1 |
Huang, J; Li, B; Li, L; Lin, W; Liu, D; Peng, Z; Proksch, P; Si, L; Wang, J; Yuan, B | 1 |
10 review(s) available for sofosbuvir and telaprevir
Article | Year |
---|---|
What's new in HCV genotype 2 treatment.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Viral Load | 2012 |
Management of HCV patients with cirrhosis with direct acting antivirals.
Topics: Algorithms; Aminoisobutyric Acids; Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Leucine; Liver Cirrhosis; Oligopeptides; Proline; Quinolines; Simeprevir; Sofosbuvir; Sulfonamides; Thiazoles; Time Factors; Uridine Monophosphate | 2014 |
Treating HCV in HIV 2013: on the cusp of change.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Coinfection; Drug Interactions; Drug Therapy, Combination; Hepacivirus; Hepatitis C; HIV Infections; Humans; Imidazoles; Leucine; Oligopeptides; Proline; Pyrrolidines; Quinolines; Sofosbuvir; Thiazoles; Treatment Outcome; Uridine Monophosphate; Valine | 2014 |
Hepatitis C treatment: an incipient therapeutic revolution.
Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Molecular Targeted Therapy; Oligopeptides; Proline; Protease Inhibitors; Sofosbuvir; Uridine Monophosphate | 2014 |
Viral hepatitis C therapy: pharmacokinetic and pharmacodynamic considerations.
Topics: Antiviral Agents; Drug Interactions; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferon-alpha; Liver Cirrhosis; Oligopeptides; Proline; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate | 2014 |
Hepatitis C management in post-transplant patients.
Topics: Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Fluorenes; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Oligopeptides; Polyethylene Glycols; Proline; Pyrrolidines; Recombinant Proteins; Recurrence; Ribavirin; Risk Factors; Simeprevir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uridine Monophosphate; Valine; Viral Load | 2015 |
Which therapeutic option for hepatitis C virus genotype 1?
Topics: Antiviral Agents; Clinical Trials, Phase III as Topic; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Oligopeptides; Proline; Randomized Controlled Trials as Topic; Simeprevir; Sofosbuvir; Viral Load | 2015 |
Management of post transplant hepatitis C in the direct antiviral agents era.
Topics: Antiviral Agents; Carbamates; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferons; Liver Transplantation; Oligopeptides; Postoperative Complications; Proline; Protease Inhibitors; Pyrrolidines; Recurrence; Ribavirin; Simeprevir; Sofosbuvir; Valine; Viral Nonstructural Proteins | 2015 |
Hepatitis C treatment from "response-guided" to "resource-guided" therapy in the transition era from interferon-containing to interferon-free regimens.
Topics: Antiviral Agents; Carbamates; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C; Humans; Imidazoles; Interferons; Isoquinolines; Oligopeptides; Proline; Pyrrolidines; Ribavirin; Sofosbuvir; Sulfonamides; Time Factors; Valine; Viral Load | 2017 |
Micro-costing analysis of guideline-based treatment by direct-acting agents: the real-life case of hepatitis C management in Brazil.
Topics: Antiviral Agents; Brazil; Carbamates; Costs and Cost Analysis; Drug Costs; Genotype; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Liver Cirrhosis; Oligopeptides; Proline; Pyrrolidines; Ribavirin; Simeprevir; Sofosbuvir; Valine | 2017 |
2 trial(s) available for sofosbuvir and telaprevir
Article | Year |
---|---|
Health-Related Quality of Life in Chronic HCV-Infected Patients Switching to Pegylated-Interferon-Free Regimens (ANRS CO20 CUPIC Cohort Study and SIRIUS Trial).
Topics: Age Factors; Aged; Antiviral Agents; Benzimidazoles; Cohort Studies; Comorbidity; Double-Blind Method; Female; Fluorenes; Health Status; Hepatitis C, Chronic; Humans; Male; Mental Health; Middle Aged; Oligopeptides; Patient Reported Outcome Measures; Polyethylene Glycols; Proline; Quality of Life; Severity of Illness Index; Sex Factors; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate | 2017 |
Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens.
Topics: Administration, Oral; Aged; Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Interferons; Kinetics; Male; Middle Aged; Oligopeptides; Ribavirin; RNA, Viral; Simeprevir; Sofosbuvir; Treatment Outcome; Viral Nonstructural Proteins | 2017 |
18 other study(ies) available for sofosbuvir and telaprevir
Article | Year |
---|---|
Design and Synthesis of Cajanine Analogues against Hepatitis C Virus through Down-Regulating Host Chondroitin Sulfate N-Acetylgalactosaminyltransferase 1.
Topics: Antiviral Agents; Diethylstilbestrol; Dose-Response Relationship, Drug; Down-Regulation; Drug Design; Enzyme Inhibitors; Gene Expression Regulation, Enzymologic; Hepacivirus; Microbial Sensitivity Tests; Molecular Structure; N-Acetylgalactosaminyltransferases; Structure-Activity Relationship | 2016 |
2-((4-Arylpiperazin-1-yl)methyl)benzonitrile Derivatives as Orally Available Inhibitors of Hepatitis C Virus with a Novel Mechanism of Action.
Topics: Administration, Oral; Animals; Antiviral Agents; Cell Line; Dogs; Drug Design; Drug Resistance, Viral; Female; Half-Life; Hepacivirus; Humans; Male; Mice; Mutation; Nitriles; Rats; Structure-Activity Relationship; Virus Replication | 2020 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Andrographolide exerts anti-hepatitis C virus activity by up-regulating haeme oxygenase-1 via the p38 MAPK/Nrf2 pathway in human hepatoma cells.
Topics: Antiviral Agents; Biliverdine; Carcinoma, Hepatocellular; Cell Line, Tumor; Diterpenes; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Enzyme Activation; Heme Oxygenase-1; Hepacivirus; Host-Parasite Interactions; Humans; Liver Neoplasms; NF-E2-Related Factor 2; Oligopeptides; p38 Mitogen-Activated Protein Kinases; Phosphorylation; RNA Interference; Signal Transduction; Sofosbuvir; Time Factors; Transfection; Uridine Monophosphate; Viral Nonstructural Proteins; Virus Replication | 2014 |
Hepatitis C treatment & management.
Topics: Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Liver Transplantation; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Recurrence; Ribavirin; Sofosbuvir; Time Factors; Uridine Monophosphate | 2014 |
Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C.
Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Oligopeptides; Proline; Quality-Adjusted Life Years; Sofosbuvir; Uridine Monophosphate | 2014 |
Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection.
Topics: Antiviral Agents; Cost-Benefit Analysis; Decision Support Techniques; Drug Therapy, Combination; Genotype; Health Care Costs; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Interferon-alpha; Liver Cirrhosis; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate | 2014 |
Resistance analysis and characterization of NITD008 as an adenosine analog inhibitor against hepatitis C virus.
Topics: Adenosine; Antiviral Agents; Cell Line; Drug Resistance, Viral; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Mutation; Oligopeptides; Protease Inhibitors; Replicon; Ribavirin; RNA, Viral; Sofosbuvir; Viral Nonstructural Proteins; Virus Replication | 2016 |
Barrier-Independent, Fitness-Associated Differences in Sofosbuvir Efficacy against Hepatitis C Virus.
Topics: Antiviral Agents; Cell Line, Tumor; Clone Cells; Drug Resistance, Viral; Gene Expression; Genetic Fitness; Genotype; Hepacivirus; Hepatocytes; Humans; Microbial Sensitivity Tests; Mutation; Oligopeptides; Sofosbuvir; Viral Nonstructural Proteins | 2016 |
Drug Pricing Evolution in Hepatitis C.
Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Discovery; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferons; Oligopeptides; Ribavirin; Ritonavir; Sofosbuvir; Switzerland; United States | 2016 |
Adoption of new agents and changes in treatment patterns for hepatitis C: 2010-2014.
Topics: Adult; Antiviral Agents; Databases, Factual; Drug Therapy, Combination; Female; Health Care Costs; Hepacivirus; Hepatitis C, Chronic; Humans; Insurance Claim Review; Interferons; Logistic Models; Male; Middle Aged; Oligopeptides; Predictive Value of Tests; Retrospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome; United States | 2016 |
Nursing Problems in Care of a Patient with Very Early HCV Infection Recurrence After Liver Transplantation: A Case Report.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferons; Liver Failure; Liver Transplantation; Oligopeptides; Postoperative Complications; Recurrence; Reoperation; Ribavirin; Sofosbuvir; Treatment Outcome; Young Adult | 2016 |
Prevention of allograft HCV recurrence with peri-transplant human monoclonal antibody MBL-HCV1 combined with a single oral direct-acting antiviral: A proof-of-concept study.
Topics: Allografts; Antibodies, Monoclonal; Antiviral Agents; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis C; Hepatitis C Antibodies; Humans; Liver Transplantation; Male; Middle Aged; Oligopeptides; Proof of Concept Study; RNA, Viral; Secondary Prevention; Sofosbuvir; Sustained Virologic Response; Transplant Recipients; Treatment Outcome | 2017 |
A Novel Inhibitor IDPP Interferes with Entry and Egress of HCV by Targeting Glycoprotein E1 in a Genotype-Specific Manner.
Topics: Amino Acid Substitution; Antiviral Agents; Carbamates; Drug Combinations; Drug Discovery; Drug Resistance, Viral; Drug Synergism; Gene Expression; Hepacivirus; Hepatocytes; High-Throughput Screening Assays; Host-Pathogen Interactions; Humans; Imidazoles; Interferon-alpha; Oligopeptides; Primary Cell Culture; Pyridines; Pyrimidines; Pyrrolidines; Sofosbuvir; Valine; Viral Envelope Proteins; Virion; Virus Internalization; Virus Release | 2017 |
Acute fulminant hepatitis B during hepatitis C virus therapy with direct-acting antivirals in a patient co-infected with HIV.
Topics: Anti-HIV Agents; Antiviral Agents; Benzimidazoles; Coinfection; Drug Substitution; Fatal Outcome; Fluorenes; Hepacivirus; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Liver Failure, Acute; Male; Middle Aged; Oligopeptides; Ribavirin; Sofosbuvir; Virus Activation | 2017 |
The frequency of acute kidney injury in patients with chronic hepatitis C virus infection treated with sofosbuvir-based regimens.
Topics: Acute Kidney Injury; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Male; Middle Aged; Oligopeptides; Proline; Risk Factors; Sofosbuvir | 2017 |
Discovery and evolution of aloperine derivatives as a new family of HCV inhibitors with novel mechanism.
Topics: Administration, Oral; Animals; Antiviral Agents; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Design; Female; Hepacivirus; Humans; Male; Mice; Mice, Inbred Strains; Microbial Sensitivity Tests; Molecular Structure; Piperidines; Quinolizidines; Structure-Activity Relationship; Time Factors; Virus Replication | 2018 |
Harzianoic acids A and B, new natural scaffolds with inhibitory effects against hepatitis C virus.
Topics: Antiviral Agents; Biological Products; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Hepacivirus; Humans; Hydroxybutyrates; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Pyrroles; RNA, Viral; Structure-Activity Relationship; Trichoderma | 2019 |